不同疗程铋剂四联疗法在中国根治幽门螺杆菌感染疗效的Meta分析

发布时间：2018-02-26 07:10

本文关键词： 幽门螺杆菌铋剂四联疗法三联疗法序贯疗法伴随疗法　出处：《第三军医大学学报》2017年10期 　论文类型：期刊论文

【摘要】：目的评价不同疗程(10 d或14 d)铋剂四联疗法在中国幽门螺杆菌感染的根除疗效及安全性。方法计算机检索2005年1月至2016年11月Pubmed、EMBASE、the Cochrane Central Register of Controlled Trials、中国知网、中国生物医学文献数据库、维普等数据库关于10 d或14 d铋剂四联疗法在中国根除幽门螺杆菌感染的随机对照试验,提取受试者的基本资料、观察指标(根除率及不良反应发生率)、研究质量等相关数据,使用Rev Man 5.3软件分析相关指标,计算RR及95%CI,使用漏斗图行发表偏倚评价。结果纳入43篇文献,共7 686例患者。合并结果显示:据意向性分析,10 d或14 d铋剂四联疗法和三联疗法根除率分别是88.96%(95%CI:87.73%~90.19%)和74.11%(95%CI:72.53%~75.69%),差异有统计学意义(RR=1.20,95%CI:1.16%~1.25%);10 d或14 d铋剂四联疗法和7 d铋剂四联疗法相比,根除率分别是87.34%(95%CI:84.87%~89.80%)、81.65%(95%CI:78.76%~84.54%)(意向性分析),差异有统计学意义(RR=1.07,95%CI:1.02%~1.12%);10 d或14 d铋剂四联联疗法与序贯疗法(RR=1.02,95%CI:0.97%~1.07%)及与伴随疗法(RR=1.01,95%CI:0.95%~1.07%)差异无统计学意义。结论 10 d或14 d铋剂四联疗法与序贯疗法及伴随疗法疗效相当,三联疗法及7 d铋剂四联疗法不作为首选治疗方案。
[Abstract]:Objective to evaluate the efficacy and safety of bismuth tetralogy in the eradication of Helicobacter pylori infection in China. Methods the Cochrane Central Register of Controlled Trials from January 2005 to November 2016 was searched by computer. China Biomedical Literature Database, Wiper and other databases on the 10th or 14th day bismuth tetralogy in China to eradicate Helicobacter pylori infection in a randomized controlled trial, to extract the basic information of the subjects, Rev Man 5.3 software was used to analyze the relevant indexes, RR and 95CII were calculated, and the funnel graph was used to report bias evaluation. The results were included in 43 articles. A total of 7 686 patients. The combined results showed that the eradication rates of bismuth quadruple therapy and triple therapy were 88.96% 95 CI: 87.73% 90.19 and 74.1111 95 CI: 72.53% 75.699.The difference was statistically significant RRR1.2095CIW 1.1695 CI: 1.161.16 and 1.25% on 10 or 14 days compared with bismuth quadruple therapy for 7 days. The eradication rates are 87.34% 84.87 and 89.8080, respectively, and there is no statistical significance between the RRN 1.0795 CI 1.02i 1.1210 d or 14d bismuth quadruple therapy and sequential therapy, as well as with the accompanying therapy RRV 1.0195 CIO 0.951.077.Conclusion there is no statistical significance between RRN 1.0195 CI 0.1.0775 and the accompanying therapy RR1.0195CIO 0.951.077.Conclusion there is no statistical significance in the difference between the RRV 1.0195CI0.975 and the bismuth quadruple therapy and sequential therapy for 10 days or 14 days. Conclusion there is no statistical significance between the two groups in addition to the accompanying therapy RR1.0195CI0.951.070.Conclusion there is no statistical significance between the two groups. Sequential therapy and concomitant therapy are equally effective. Triple therapy and 7 d bismuth tetralogy were not the first choice.
【作者单位】：第三军医大学西南医院全军消化病研究所;第三军医大学大坪医院野战外科研究所消化内科;
【分类号】：R57

【相似文献】